logo
Plus   Neg
Share
Email

5 Top Gainers In Healthcare Sector (DCPH, MBIO, BCEL...)

pharmaup-aug13-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. Deciphera Pharmaceuticals Inc. (DCPH)

Gained 79.95% to close Tuesday's (Aug.13) trading at $35.90.

News: The Company announced positive top-line data from its pivotal phase III clinical study of Ripretinib in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors, dubbed INVICTUS.

In the trial, Ripretinib demonstrated a median progression free survival of 6.3 months compared to 1.0 month in the placebo arm and significantly reduced the risk of disease progression or death by 85% compared to placebo.

Based on the positive INVICTUS data, the Company expects to submit a New Drug Application to the FDA for Ripretinib for the treatment of patients with advanced gastrointestinal stromal tumors who have received prior treatment with imatinib, sunitinib, and regorafenib in the first quarter of 2020.

The Company also reported encouraging updated data from its ongoing phase I study of Ripretinib in patients with second-line through fourth-line plus gastrointestinal stromal tumors.

2. Atreca Inc. (BCEL)

Atreca Inc. is a biopharmaceutical company developing novel antibody-based immunotherapeutics to treat a range of solid tumor types.

Gained 25.78% to close Tuesday's trading at $14.49.

News: The Company announced financial results for the second quarter ended June 30, 2019. This is the Company's first earnings report as a public company.

The net loss was $17.9 million or $3.67 per share in the second quarter of 2019 compared to a net loss of $8.67 million or $4.13 per share in the year-ago quarter. No revenue has been generated.

Recent event:

The Company went public on the Nasdaq Global Select Market on June 20, 2019, offering its shares at a price of $17.00 per share.

Pipeline and Near-term Catalysts:

The Company's lead product candidate is ATRC-101, a monoclonal antibody in preclinical development that has demonstrated reactivity with ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients.

The company expects to file an IND application for ATRC-101 in late 2019 and initiate a phase 1b clinical trial in patients with solid tumors in early 2020, subject to FDA approval of IND application.

3. Mustang Bio Inc. (MBIO)

Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.

Gained 22.84% to close Tuesday's trading at $3.55.

News: The Company announced a $9.28 million grant from the California Institute for Regenerative Medicine to fund an ongoing phase I trial of CAR T therapy MB-103 in HER2-positive breast cancer with brain metastases. The trial is expected to enroll 21 patients at the City of Hope.

Near-term Catalyst:

The MB-107 IND is expected to be transferred from partner St. Jude to Mustang in the fourth quarter of 2019. In April of this year, promising data from a phase I/II clinical trial of MB-107 for severe combined immunodeficiency, also referred to as "bubble boy disease" was published in the New England Journal of Medicine.

The Company expects to initiate a multi-center Phase 1/2 clinical trial of MB-102 in acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndromes.

4. G1 Therapeutics Inc. (GTHX)

G1 Therapeutics is a clinical-stage oncology company.

Gained 18.54% to close Tuesday's trading at $37.28.

News: No news

Near-term Catalysts:

-- Detailed data from the phase II trial of Trilaciclib in combination with chemotherapy in women with metastatic triple-negative breast cancer will be presented at a medical meeting later this year. Preliminary overall survival (OS) results from the phase II trial demonstrated women with metastatic triple-negative breast cancer lived significantly longer when receiving Trilaciclib and chemotherapy compared with women receiving chemotherapy alone.
-- The Company expects to submit marketing applications for Trilaciclib in the U.S. and Europe for myelopreservation in small cell lung cancer in 2020.

5. AgeX Therapeutics Inc. (AGE)

AgeX Therapeutics is a biotechnology company focused on therapeutics for human aging.

Gained 17.39% to close Tuesday's trading at $2.97.

News: No news

Pipeline:

The Company's investigational products include AGEX-BAT1 for Type 2 diabetes; AGEX-VASC1 for metabolic imbalances in aging; AGEX-iTR1547 for the treatment of congestive heart failure; and Renelon, a first-generation iTR product candidate designed to promote scarless tissue repair, all under preclinical testing.

For comments and feedback contact: editorial@rttnews.com

Follow RTT
>